ABSTRACT
Introduction
Extracorporeal membrane oxygenation (ECMO) provides temporary life support for children with severe respiratory or cardiac failure. Since 1990, more than 29,000 children with respiratory failure have received ECMO. The overall survival rate reported by the Extracorporeal Life Support Organization (ELSO) is 75% in neonates and 56% in children.
(1) Despite its technical complexity and the need for experienced staff (usually designated as the "ECMO-team"), ECMO support has clearly achieved an important role in pediatric critical care. Although many previous studies describe ECMO treatment in neonatal or pediatric respiratory failure, (2-10) the impact of different veno-venous ECMO methods has remained unconsidered. ELSO provides a data registry dating back to 1989. All ECMO centers, which are members of ELSO, report their ECMO cases, devices, complications and follow-up status to this registry in an anonymous form. For this purpose, each center uses standardized data capture forms for each patient. Since 1990, more than 30,000 treatments were added to the database containing data from neonatal, pediatric and adult ECMO cases. Currently, data from 116 US and 14 international centers are submitted to ELSO. Submission of cases to the ELSO registry is voluntary. A database of information relating to 10 years of international experience was provided by ELSO for this study. The objective of this study was to compare complications and survival between veno-venous two-site ECMO (VV ECMO) and veno-venous double lumen ECMO (VVDL ECMO) in infants with respiratory failure.
Methods
This study was designed as a retrospective chart review study. Until recently, most pediatric ECMO studies reported on neonates (body weight 2.5-3.5kg) and/or children (body weight > 10kg) but not specifically on infants (body weight 4-10 kg). The median weight of an infant of 6 months according to international percentile curves is 8 kg body weight for boys and 7,2 kg body weight for girls. (11) We therefore, set the cutoff point for the inclusion criteria at < 7kg body weight and age of > 32 days for infants which were included in this study. This study aims to fill, or at least narrow, this gap. From 1999 until 2009, the registry recorded 9,086 ECMO runs in infants with a body weight Ě 7kg. Using the 'mode of bypass' data field as a sorting tool, two groups of patients were identified among all infants older than 32 days: the VV two-site ECMO group and the VVDL ECMO group. Two hundred and seventy infants met the inclusion criteria of which 236 infants (87%) were treated with VVDL ECMO and 34 infants (13%) were treated with VV two-site ECMO. Children who had received other modes of ECMO were not included in this study. The decision to use VV ECMO was made at each centre according to their own ECMO criteria. Only data from the first ECMO run were analyzed. Anonymity of the data could be assured as data were related to patient identification (ID) numbers in the ELSO registry. Each institution approved data reported to ELSO through their local institutional review board. The Hospital Research Ethics Committee reviewed the study protocol. And the requirement for ethical approval was waived. 
Data management

Results
Demographic data
Demographic data is shown in table 1. There was no significant difference noted between genders. Infants in the VVDL group had a lower gestational age (30 vs. 39 weeks, p=0.01) but the age at the start of ECMO did not differ significantly. However, the birth weights (1.8 vs. 3.7kg BW, p=0.014) and current weights (3.9 vs. 4.5, p=0.049) observed in the VVDL group were significantly lower. The primary diagnoses were defined by ICD 9 codes (International Classification of Disease, 9th Revision) and classified into disease groups as listed in table 2. The most common primary diagnosis was viral pneumonia: 44% in the VVDL group and 21% in the VV two-site group (e.g. respiratory syncytial virus, adenovirus and parainfluenza virus). Pre-ECMO data Groups showed no difference in total amount of pre-ECMO support (96 vs. 91%). Analyses of the pre-ECMO support stage in specific categories, however, showed a significant difference when vasopressors / inotropic drugs were administered (64 vs. 82 %, p=0.03).
ECMO course data
There were no differences between groups in relation to the mode of cannulation (percutaneous or surgical cannulation 170/66 vs. 23/11) used or the in relation to the duration of ventilation observed before ECMO was started (102.5(44.5/191.7) vs. 59(22.2/172) hours). The duration of ECMO was significantly shorter in the VV two-site group (137(90/208) vs. 203(128/336) hours, p=0.01). There was no significant difference noted between groups with regards to the ventilation mode used pre-ECMO. Twenty-four hours after the onset of ECMO, PIP and MAP were significantly higher in the VV two-site group (22(20/27) vs. 26(20/31), p=0.0174 and 12(10/14) vs. 14(10/18), p=0.049) than in the VVDL group, respectively. Complications ECMO-treatment without complications was found in 14% of the VVDL group and in 21% of the VV two-site group. Eighty-six percent of the VVDL group and 79% of the VV two-site group experienced at least one complication during ECMO, with a median of 2 complications per patient in both cohorts. The most frequent complications are classified and listed in table 3. The most frequent mechanical complication was defined as 'cannula problems' (20% of all children). This occurred more frequently in the VVDL group than in the VV two-site group (21% vs. 12%). Outcome ECMO survival rates were 82% in the VVDL group and 68% in the VV two-site group. Overall, 217 infants from 270 study patients (80%) survived ECMO of which 71% in the VVDL group and 56% in the VV two-site group were discharged alive from the ICU. This difference was not statistically significant.
Discussion
In this chart review study of infants with respiratory failure, no difference in the total complication and overall survival rate was observed between the VV twosite and the VVDL ECMO group. Among a number of potential complications associated with ECMO, intracranial hemorrhage or infarction, during bypass, is perhaps the most devastating. This analysis showed a neurological complication rate of approximately 0.5-6% in both groups, with a marginally lower rate in the VV two-site group. The etiology of these neurological injuries is multifactorial: abrupt changes in local and systemic blood pressure, ischemia/reperfusion, anticoagulation and venous hypertension caused by distal internal vein ligation are reported to play a contributory role. (4) The duration of pre-ECMO mechanical 
VVDL VV
Viral pneumonia 44 21
Bacterial pneumonia 3 6
Infection (e.g. acute bronchiolitis, pertussis)
18
Respiratory disease (e.g. tracheal stenosis, primary pulmonary hypertension)
21
Respiratory insufficiency, non-traumatic 9 6
ARDS
9
Congenital heart disease 4 6
Other 8 1 5
Data are presented as a percentage (%) for categorical variables. Statistical significance was accepted at p < 0.05. ARDS, acute respiratory distress syndrome; VV, veno-venous two site ECMO group; VVDL, veno-venous double lumen ECMO group.
ventilation did not differ significantly between groups. Swaniker et al. (5) reported that the only pre-ECMO variable that correlated with survival was pH and they were surprised that the pre-ECMO period of mechanical ventilation was not predictive of outcome, as shown previously for adults. (12, 13) With regard to ECMO, they also observed that survival was strongly associated with the presence of renal failure and the need of inotropes. In both study groups, some of the venous cannulae were placed percutaneously (VVDL 72%, VV two-site 67% To identify possible differences in the clinical status between groups and explain our findings, we looked at the primary diagnoses and total pre-ECMO support provided to each patient before starting ECMO. We found that primary diagnoses (table 2) , ventilation time before ECMO and total pre-ECMO support (96% in VVDL versus 91% in the VV two-site) did not differ between groups. All these findings suggest that groups did not differ in their clinical status when ECMO support was initiated. Although analysis of all the single, specific criteria of pre-ECMO support showed a significantly higher need of inotropic support and also significantly higher MAP and PIP values after 24 hours of ECMO in the VV two-site group (table 3) , it cannot be concluded that these infants were more unwell or sicker than those in the VVDL group. This is supported by the results of Roberts et al. (3) who showed that the level of inotropic support provided to ECMO patients during an ECMO run did not provide a good tool for distinguishing between survivors and nonsurvivors. Diagnosis was much more relevant for this purpose. Duration of ECMO was significantly shorter in the VV two-site group, but it is not possible to judge whether VV twosite cannulation improves outcomes compared with VVDL techniques, since this finding may also be influenced by the lower survival in the VV two-site group (56% vs. 71%, p=0.071), leading to earlier discontinuation of ECMO at death. Pettignano et al. (2) reported a median ECMO duration of 218 hours in 68 VV patients, with a survival rate at discharge of 77%. In this analysis, ECMO duration in both groups was shorter and the overall survival at discharge was 69%. 
Conclusions
The total complication rate was found to be similar in both groups. No difference was found in survival rates between the two groups. Neither of the two-cannulation methods -veno-venous two-site or veno-venous double lumen ECMO 
